Matching articles for "revumenib"
Ziftomenib (Komzifti) for Acute Myeloid Leukemia (online only)
The Medical Letter on Drugs and Therapeutics • March 16, 2026; (Issue 1750)
Ziftomenib (Komzifti – Kura), an oral menin inhibitor,
has been approved by the FDA for treatment of adults
with relapsed or refractory acute myeloid leukemia
(AML) with a susceptible nucleophosmin 1...
Ziftomenib (Komzifti – Kura), an oral menin inhibitor,
has been approved by the FDA for treatment of adults
with relapsed or refractory acute myeloid leukemia
(AML) with a susceptible nucleophosmin 1 (NPM1)
mutation who have no satisfactory alternative
treatment options. It is the second oral menin inhibitor
to be approved in the US for this indication; revumenib
(Revuforj) was approved in October 2025 for use in
patients ≥1 year old.
Revumenib (Revuforj) for Acute Leukemia (online only)
The Medical Letter on Drugs and Therapeutics • January 6, 2025; (Issue 1719)
Revumenib (Revuforj – Syndax), an oral menin
inhibitor, has been approved by the FDA for treatment
of relapsed or refractory acute leukemia in patients
≥1 year old with a lysine methyltransferase 2A...
Revumenib (Revuforj – Syndax), an oral menin
inhibitor, has been approved by the FDA for treatment
of relapsed or refractory acute leukemia in patients
≥1 year old with a lysine methyltransferase 2A gene
(KMT2A) translocation. It is the first menin inhibitor to
be approved in the US.